Galapagos NV has acquired Cangenix Ltd. for $1.9 million and a potential further payment of $708.7 million based on the achievement of certain conditions. The acquisition adds a structure-based drug discovery platform to Galapagos’ Argenta service offering. Argenta will integrate all of Cangenix’s assets, personnel and service contracts with its capabilities in hit finding and medicinal chemistry. The Cangenix team will join Argenta but will continue to operate the platform in its premises...